INCLUSION OF IVERMECTIN IN THE FIRST THERAPEUTIC LINE OF ACTION FOR COVID-19 (2020/05/02 Peru, PDF (some text inside this post))

[-] TrumpLyftAlles | 1 points | May 26 2020 00:08:56

Apparently this document is the basis for adding ivermectin to Peru's protocol for COVID-19. Dr. Aguirre included the important things known at the time, with the exception of the Broward County, Florida MD's report of success with ivermectin. There wasn't much known on May 2 (date on the doc) and there's not much more known now, mostly the Bangladesh report -- which like the Dominican Republic and Broward Country announcements, are not science and are not going to persuade the public health community and political leadership of the US.

Whoops, this is new!! A formal paper on how ivermectin works to stop covid19!

INCLUSION OF IVERMECTIN IN THE FIRST THERAPEUTIC LINE OF ACTION FOR COVID-19

A very significant decrease in the Mortality Rate is reported with its use Gustavo Aguirre Chang. Doctor graduated from UNMSM, with Post Graduate Programs in Management and Occupational Health. Lima Peru. May 2, 2020.

SUMMARY:

The existing evidence regarding the use of ivermectin in COVID-19 is reviewed. A report is also made of the cases treated at the local level.

A study recently published in the journal Antiviral Research obtained participants from 169 hospitals around the world, this study includes a high number of patients treated with ivermectin: 704 and their corresponding 704 controls. The study results indicate that the case fatality rate in patients who used ivermectin was 6.1 times lower compared to patients who did not use ivermectin (1.4 vs. 8.5%, p <0.0001).

For his part, in the Dominican Republic, the Pulmonologist J. Tavares reports that he is treating 247 patients with ivermectin with a favorable response in all cases and has not reported any fatal cases.

Similarly, at the local level, although to date there are not many documented cases, the case fatality rate has been 0% and it is also observed that in 100% of the cases treated with ivermectin there is an improvement in the illness and resolution of fever within 48 hours of starting treatment.

A new therapeutic scheme is presented according to the degree of severity and response to treatment, prepared based on the experience of patients treated locally.

In the final part, an evaluation of the Risk-Benefit of the use of ivermectin is made, the conclusion is given that, since there is practically no risk in its use, it is recommended to formalize its inclusion in the first line of therapeutic action for COVID-19.

Finally, Recommendations are given mainly related to the supply in Health Establishments throughout the country